Veradermics: $150 Million Series C Raised For Advancing Late-Stage Trials Of VDPHL01
By Amit Chowdhry ● Yesterday at 11:39 PM
Veradermics, a dermatologist-founded, late clinical-stage biopharmaceutical company developing first-in-class treatments for common dermatologic conditions, has announced the completion of an oversubscribed $150 million Series C financing round. The funding round was led by SR One, with participation from major life sciences investors including Viking Global Investors, Marshall Wace, Invus, abrdn Inc., Columbia Threadneedle Investments, Infinitium, LifeSci Venture Partners, and returning investors Longitude Capital, Suvretta Capital Management, and Surveyor Capital (a Citadel company), among others.